Chronic rhinitis: intranasal steroids first — the AU general practice approach

Chronic rhinitis is one of the highest-volume presentations in Australian general practice, yet it remains one of the most undertreated. Approximately 19% of Australians have chronic rhinitis of any subtype — allergic, non-allergic, or mixed — and the condition substantially impairs sleep, productivity, and quality of life. The most preventable complication is rhinitis medicamentosa, caused by topical decongestant overuse and affecting a large proportion of patients who have been using pharmacy-bought decongestant sprays for weeks or months without guideline-guided instruction.

The management framework from eTG Respiratory and ARIA is clear: intranasal corticosteroid (INCS) spray is first-line for persistent congestion in every subtype, saline rinse is foundational, and antihistamines are targeted to the allergic phenotype. The challenge in general practice is identifying the correct subtype — because the treatment additions beyond INCS differ substantially between allergic, vasomotor, drug-induced, and hormonal rhinitis.

A. Core clinical — the AU general-practice framework

Classification

eTG Respiratory and ARIA recognise four overlapping categories of chronic rhinitis:

Chronic allergic rhinitis (CAR) — IgE-mediated, driven by perennial allergens (house dust mite, pet dander, mould) or seasonal pollen (ryegrass, birch, cypress). Prominent symptoms include nasal itch, sneezing, watery rhinorrhoea, and conjunctivitis. Most patients have an atopic background — asthma, eczema, food allergy.

Non-allergic rhinitis (NAR) — nasal symptoms without IgE mechanism, accounting for approximately 25–30% of all chronic rhinitis. Major subtypes:

• Vasomotor (idiopathic) — triggered by temperature change, strong odours (perfume, cleaning products), alcohol, cigarette smoke, or emotion; congestion and rhinorrhoea predominate
• Gustatory — watery rhinorrhoea within minutes of eating, especially spicy or hot food (vagally mediated)
• Drug-induced — ACE inhibitors (bradykinin mechanism), alpha-blockers, NSAIDs (aspirin-exacerbated respiratory disease phenotype), OCP/HRT (oestrogenic mucosal swelling), PDE5 inhibitors (sildenafil, tadalafil)
• Hormonal — pregnancy rhinitis (third trimester, ~20% of pregnant women), menstrual cycle variation, hypothyroidism
• Occupational — flour, latex, wood dust, isocyanates, animal proteins; worsens at work, improves on weekends and holidays
• NARES — non-allergic rhinitis with eosinophilia syndrome; eosinophilic mucosal inflammation without systemic IgE; highly responsive to INCS
• Atrophic — mucosal and glandular atrophy, turbinate resorption, crusting, foul odour (ozaena); primary (Klebsiella ozaenae) or secondary to surgery or radiotherapy

Rhinitis medicamentosa — rebound congestion from topical decongestant (xylometazoline, oxymetazoline) use beyond five days.

Mixed rhinitis — coexisting allergic and non-allergic features; the most common pattern in adults (~40% of cases). Both components need addressing — INCS covers both, but antihistamine benefit is limited to the allergic component.

History

A structured history per ASCIA and eTG:

• Pattern: seasonal vs perennial; nocturnal vs diurnal; episodic vs continuous
• Trigger inventory: allergens (pollens, dust mite, pets, mould); temperature change; odours; alcohol; food; emotions; workplace exposure
• Medication review: ACE inhibitors, NSAIDs, alpha-blockers, OCP, PDE5 inhibitors — temporal link to symptom onset; topical decongestant use (duration, frequency — more than 5 days suggests rhinitis medicamentosa)
• Atopic history: asthma, eczema, food allergy, anaphylaxis
• Occupational: improves on weekends or holidays — suspect occupational rhinitis
• Red flags: unilateral persistent symptoms, epistaxis, facial pain or numbness, anosmia combined with polyps and aspirin sensitivity (Samter’s triad), crusting or ulceration (granulomatosis with polyangiitis), clear unilateral discharge post-trauma (CSF rhinorrhoea)

Examination

Anterior rhinoscopy with otoscope or nasal speculum:

• Allergic: pale, boggy, swollen turbinates; clear watery secretions
• Vasomotor: erythematous swollen turbinates; clear secretions
• NARES: pale mucosa; less itch than allergic
• Polyps: pale grey glistening masses from middle meatus — suggest chronic rhinosinusitis with nasal polyps
• Atrophic: wide nasal cavity, adherent crusts, foul smell
• Septal perforation: cocaine use, prolonged decongestant, granulomatosis with polyangiitis

Check the posterior pharynx for cobblestoning (post-nasal drip) and the chest for wheeze (asthma coexists in up to 40% of allergic rhinitis patients — the two conditions share bidirectional Th2 inflammation pathways).

Investigations

Chronic rhinitis is primarily a clinical diagnosis. Investigate when allergen-specific therapy is planned or diagnostic uncertainty exists:

• Specific IgE (ImmunoCAP) — MBS 71093 (up to 4 allergens); 71095 panels. Alternative to skin prick test when SPT is contraindicated
• FBC + eosinophils — MBS 65070 — supports NARES workup
• TFTs — MBS 66719 — if hormonal rhinitis (hypothyroidism) suspected
• ANCA — MBS 71109 — if granulomatosis with polyangiitis suspected
• CT paranasal sinuses — MBS 56419 range — refractory disease, polyp suspicion, structural cause

Management hierarchy

Per ASCIA, ARIA, and eTG:

Foundation for all subtypes:

1. Identify and remove the driver — substitute ACE inhibitor with ARB; stop topical decongestant; trial of ceasing NSAID or OCP if drug-induced rhinitis suspected
2. Saline nasal irrigation — large-volume isotonic rinse two to three times daily. Use sterile or cooled-boiled water; never tap water
3. Avoid first-generation antihistamines (chlorpheniramine, promethazine, diphenhydramine) — sedation, anticholinergic burden, falls risk in older adults, driving impairment

Mild allergic rhinitis:

• Second-generation oral antihistamine — loratadine 10 mg, cetirizine 10 mg, fexofenadine 180 mg, desloratadine 5 mg, or bilastine 20 mg
• Or intranasal azelastine for faster onset

Moderate-severe persistent rhinitis (any subtype with persistent congestion):

• INCS first-line — fluticasone furoate (Avamys) 2 sprays each nostril daily; mometasone furoate (Nasonex); budesonide (Rhinocort). Technique: head slightly forward, spray toward outer eye — not toward septum. Full effect at one to two weeks of daily use
• Dymista (fluticasone + azelastine) — PBS Authority Required (Streamlined) for moderate-severe allergic rhinitis uncontrolled on INCS monotherapy; superior to monotherapy per Carr MP4002 trial (JACI 2012)

Non-allergic subtype add-ons:

• Rhinorrhoea-predominant vasomotor or gustatory NAR → intranasal ipratropium 0.03% 2 sprays per nostril two to three times daily; for gustatory: 15–20 minutes pre-meal
• NARES → INCS first-line (highly responsive)
• Rhinitis medicamentosa → cease topical decongestant + INCS bridge (see Section C)
• Pregnancy rhinitis → saline + budesonide INCS (Category A)

Refractory step-up:

• Short oral prednisolone 25–30 mg daily for 5–7 days for severe acute flare; limit to one to two courses per year
• Allergen immunotherapy (SLIT/SCIT) for refractory allergic phenotype — specialist-initiated, disease-modifying, not PBS-subsidised
• Biologic therapy (dupilumab, omalizumab, mepolizumab) for severe chronic rhinosinusitis with nasal polyps — PBS Authority Required, specialist-initiated

B. Evidence appraisal — INCS, saline, and immunotherapy

INCS outperforms antihistamines for moderate-severe rhinitis

Wallace et al. (JACI 2008) established that intranasal corticosteroids are superior to oral antihistamines across all rhinitis symptoms — including itch and sneezing as well as congestion — for moderate-severe persistent disease. This finding underpins the ARIA recommendation that INCS is first-line for moderate-severe rhinitis, with antihistamines as add-on for mild-intermittent disease only.

The counterintuitive clinical pearl: INCS is effective in non-allergic rhinitis subtypes (vasomotor, NARES, mixed) as well as allergic — the anti-inflammatory effect is not allergen-specific. This makes INCS the universal first-line choice for any chronic rhinitis with persistent congestion, regardless of phenotype.

Saline irrigation — under-used yet highly effective

Hermelingmeier et al. (Am J Rhinol Allergy 2012) and the Chong Cochrane review 2016 both confirm that saline nasal irrigation significantly reduces symptoms and medication requirements in chronic rhinitis and chronic rhinosinusitis. It is cheap, accessible, has no meaningful side effects at correct technique, and is systematically underutilised in clinical practice.

Key technique point: always use sterile or cooled-boiled water. Tap water carries a very small risk of primary amoebic meningoencephalitis (Naegleria fowleri) — a rare but fatal infection documented in warm-water regions of Australia.

Allergen immunotherapy — disease-modifying for the allergic phenotype

Penagos et al. (JACI 2017) meta-analysis confirmed significant symptom and medication score reductions with SLIT for grass pollen and house dust mite in adults and children. The GAP trial (Allergy 2017) showed grass SLIT reduced new-onset asthma in rhinitis patients — a disease-modifying effect not achievable with symptomatic pharmacotherapy alone.

Australian SLIT products: Acarizax/Actair (house dust mite), Oralair/Grazax/Itulazax (grass pollen). None are PBS-subsidised — private cost ~$1,500–3,000 per year. Require specialist clinical immunologist prescription and follow-up.

Montelukast: reserved role with mandatory warning

Wilson Cochrane 2011 showed montelukast provides modest benefit in allergic rhinitis, inferior to INCS. The TGA Boxed Warning issued 2020 flagged neuropsychiatric adverse events — mood disturbance, sleep disruption, suicidal ideation — restricting its use. Current position: reserve montelukast for patients with coexisting asthma and rhinitis where INCS plus antihistamine is inadequate, with explicit documented counselling on mental health side effects.

C. Rhinitis medicamentosa — a preventable cycle

Rhinitis medicamentosa deserves specific attention because it is common, entirely preventable, and frequently missed or misdiagnosed as chronic infective rhinosinusitis.

The mechanism: alpha-agonist topical decongestants (xylometazoline, oxymetazoline) cause direct vasoconstriction of nasal mucosal vessels, relieving congestion within minutes. Repeated use beyond five days causes downregulation of alpha-adrenoceptors. When the spray wears off, rebound vasodilatation produces congestion worse than the original complaint, driving the patient back to the spray. The cycle becomes self-perpetuating. Patients present with severe nasal obstruction and a history of progressively escalating topical decongestant use — often multiple times per day.

Prevention: Counsel all patients at the time of any decongestant recommendation — prescription or OTC — to use for a maximum of five consecutive days. Document this advice.

Management:

1. Cease the topical decongestant entirely — abrupt cessation is required; there is no evidence for tapering
2. Begin INCS immediately — fluticasone furoate (Avamys) 2 sprays per nostril daily as the standard bridge; continue four to six weeks
3. Saline rinse two to three times daily during the rebound period
4. Short-course oral prednisolone 25–30 mg daily for 5–7 days if rebound is severe and the patient cannot tolerate abrupt cessation
5. Safety-net: expect a difficult rebound period of one to two weeks; plan a review at two weeks

Recurrence is common — document the episode in the medical record and reinforce the five-day rule at every future relevant encounter.

D. Australian operations

PBS (verified via pbs.gov.au):

• INCS (fluticasone furoate, mometasone, budesonide, ciclesonide, beclomethasone) — General Schedule; many also OTC
• Fluticasone + azelastine (Dymista) — Authority Required (Streamlined) for moderate-severe AR uncontrolled on monotherapy
• Second-generation antihistamines (loratadine, cetirizine, fexofenadine, desloratadine, levocetirizine, bilastine) — General Schedule or OTC
• Intranasal ipratropium 0.03% — General Schedule
• Montelukast — Authority Required (Streamlined) for asthma; TGA Boxed Warning 2020 for neuropsychiatric events
• Topical decongestants (xylometazoline, oxymetazoline) — OTC; counsel 5 days maximum
• SLIT products (Acarizax, Actair, Oralair, Grazax, Itulazax) — NOT PBS-subsidised; private ~$1,500–3,000/year
• Dupilumab — Authority Required for severe CRS with nasal polyps; specialist initiation only

MBS (via MBS Online):

• Standard consults: 3 / 23 / 36 / 44
• Specific IgE: 71093 (up to 4 allergens), 71095 (panels)
• FBC: 65070 | TFTs: 66719 | ANCA: 71109
• CT paranasal sinuses: 56419 range
• Telehealth: 91790 / 92029 / 92060 (existing-relationship rule applies)
• GPCCMP: 965 (preparation) / 967 (review) — chronic rhinitis qualifies as a chronic condition
• MHTP: 2715 / 2717 — applicable if rhinitis is significantly impairing mood or sleep
• ATSI Health Assessment: 715

GPCCMP eligibility: chronic rhinitis (allergic or non-allergic) qualifies under the GP Chronic Condition Management Plan structure (replacing CDM from July 2025). Relevant plan elements: trigger identification, INCS technique education, asthma and sleep apnoea co-management, referral pathway to clinical immunologist if immunotherapy indicated, and thunderstorm asthma action plan for spring-pollen-sensitised patients in south-east Australia.

Medico-legal flags:

• First-generation antihistamines impair driving — document counselling; ensure patients do not drive after sedating antihistamines
• Anaphylaxis history in severe allergic rhinitis — prescribe adrenaline autoinjector and complete an ASCIA Action Plan
• Pregnancy — document INCS safety tier (budesonide Category A per TGA); avoid oral pseudoephedrine in the first trimester, and in hypertension or ischaemic heart disease
• Montelukast — mandatory documented counselling on neuropsychiatric adverse events before prescribing

E. Special populations

Older adults. First-generation antihistamines are high-risk — anticholinergic burden, falls, urinary retention, cognitive effects. Use exclusively second-generation antihistamines. Topical decongestants can raise blood pressure significantly — caution in hypertension, ischaemic heart disease, and benign prostatic hypertrophy. Older adults are also at higher risk of rhinitis medicamentosa from prolonged OTC decongestant use without medical review.

Pregnancy. Pregnancy rhinitis affects approximately 20% of pregnant women, peaking in the third trimester from oestrogenic mucosal swelling, and resolves within two weeks postpartum. Management: saline rinse (first-line, no safety concerns), budesonide INCS (Category A safety data). Oral antihistamines loratadine and cetirizine are Category B2. Avoid oral pseudoephedrine in the first trimester. Reassure that the condition is hormonally driven and resolves postpartum.

Children and adolescents. Chronic mouth-breathing from nasal obstruction affects dental and facial development — refer early if persistent. Paediatric allergic rhinitis commonly coexists with asthma; aggressive rhinitis treatment may improve lower airway control. INCS technique requires parental supervision initially. SLIT has expanding TGA paediatric approvals — discuss with a clinical immunologist.

Athletes. Bilastine 20 mg is the preferred antihistamine — minimal CNS penetration, not sedating, not on the WADA prohibited list at standard doses. Intranasal corticosteroids are not prohibited at standard doses for nasal use; check current WADA status for oral corticosteroids if systemic courses are considered. Intranasal ipratropium is not prohibited.

Thunderstorm asthma. Patients with grass pollen sensitisation in south-east Australia face elevated risk during spring thunderstorm events. Ensure all pollen-sensitised patients — including those without prior asthma — have a written asthma action plan and adequate INCS plus antihistamine supply before spring. Refer to the Department of Health thunderstorm asthma resources and the VicEmergency notification system.

When to escalate

Refer or escalate when:

• Urgent (same-day or ED): anaphylaxis; thunderstorm asthma exacerbation with bronchospasm; suspected orbital or intracranial complication of rhinosinusitis
• Same-week:
  • Unilateral persistent symptoms, epistaxis, or facial numbness — tumour (inverted papilloma, SCC) must be excluded; ENT same-week referral
  • Suspected granulomatosis with polyangiitis (crusting, ulceration, saddle nose, systemic features, ANCA positive) — rheumatology and ENT
• Routine referral:
  • Allergen immunotherapy candidacy (refractory allergic rhinitis, patient motivated and informed of cost) → clinical immunologist
  • Nasal polyps or severe CRS with polyps, biologic candidacy (dupilumab) → ENT
  • Structural cause (septal deviation, turbinate hypertrophy) refractory to medical therapy → ENT for surgical options
  • Occupational rhinitis — document exposure; refer to occupational physician; consider SafeWork Australia notification if compensable
  • Refractory non-allergic rhinitis not responding to adequate INCS plus ipratropium trial

What this article is and is not

This is general health information drawn from current Australian clinical guidelines — ASCIA Allergic Rhinitis Clinical Update, Therapeutic Guidelines (eTG) Respiratory, Australian Medicines Handbook, NPS MedicineWise — and major rhinitis trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation, medication, and referral are made in partnership with your GP and treating clinicians.

For consumer-facing resources: HealthDirect — Hay fever, ASCIA patient information, Better Health Channel — Hay fever, Allergy and Anaphylaxis Australia.

---

Sources cited

1. ASCIA Allergic Rhinitis Clinical Update
2. Therapeutic Guidelines (eTG) — Respiratory: Allergic rhinitis
3. Australian Medicines Handbook
4. NPS MedicineWise
5. TGA — Montelukast Boxed Warning 2020
6. ARIA — Allergic Rhinitis and its Impact on Asthma
7. EPOS 2020 — European Position Paper on Rhinosinusitis
8. Carr W et al — Dymista MP4002 trial (JACI 2012)
9. Hermelingmeier KE et al — Saline irrigation (Am J Rhinol Allergy 2012)
10. Chong LY et al — Saline irrigation Cochrane 2016
11. Wilson DR et al — LTRA for rhinitis Cochrane 2011
12. Penagos M et al — SLIT meta-analysis (JACI 2017)
13. GAP trial — grass SLIT and asthma prevention (Allergy 2017)
14. MBS Online
15. PBS
16. HealthDirect — Hay fever
17. Better Health Channel — Hay fever